<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02849977</url>
  </required_header>
  <id_info>
    <org_study_id>RM-493-013</org_study_id>
    <nct_id>NCT02849977</nct_id>
  </id_info>
  <brief_title>Genetic Testing and Phenotypic Characterization of Severely Obese Pediatric and Adult Volunteers</brief_title>
  <official_title>Genetic Testing and Phenotypic Characterization of Severely Obese Pediatric and Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rhythm Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rhythm Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this screening study is to identify people who have a rare genetic cause of
      obesity - specifically three genetic variants (a change in the DNA structure) of the POMC,
      PCSK1 and LepR genes that are currently known to result in obesity.

      This screening study will not include any investigational drugs. You will be asked to provide
      a DNA sample and answer some questions about your medical history and hunger.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 28, 2016</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Identification of individuals with POMC, LepR or PCSK1 genetic mutations</measure>
    <time_frame>1 Year</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">5000</enrollment>
  <condition>Pro-opiomelanocortin (POMC), Proprotein Convertase Subtilisin/Kexin Type 1 (PCSK1) and Leptin Receptor (LepR) Gene Mutations</condition>
  <eligibility>
    <study_pop>
      <textblock>
        The objective is to identify individuals with severe, early onset morbid obesity (EOMO),
        who are aged 2 years of age or older, and are suspected to be either homozygous, compound
        heterozygous or heterozygous for loss of function mutations in the POMC, PCSK1 or LepR
        gene, leading to a clinical presentation of Melanocortin 4 (MC4) pathway deficiency
        obesity. Individuals may be contacted for further assessment of clinical features
        (including questionnaires on past weight and medical history and current hunger and feeding
        behavior symptoms) and/or participation in future Rhythm clinical trials.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Able to provide voluntary, written informed consent with comprehension of all aspects
             of the protocol, prior to any study procedures. If participant is a child age 2 to 17
             years, or an adult with intellectual disabilities, the Parent or guardian is able to
             communicate well with the investigator, to understand and comply with the requirements
             of the study, and be able to understand and sign the written informed consent. Assent
             will be provided by a child who cannot consent for himself or herself according to the
             requirements of each institution.

          -  Severe EOMO, preferably with past history evidence suggestive of onset prior to age 6
             years at the time of identification.

          -  For children between ages 2 through 17 years, severe obesity is defined as weight &gt;
             40% above (i.e., &gt; 1.4 x) the 95th percentile weight for any age range (using a
             provided reference table of values by year from ages 2 to 18).

               -  Subjects can be included with BMI &lt; 40 kg/m2 or &lt; 1.4x the 95th percentile, if in
                  the investigators estimation the proband demonstrates a Z score difference &gt; 1
                  between proband and any other siblings. And/or the proband demonstrates a BMI
                  difference &gt; 10 kg/m2 between proband and parents.

          -  For adults age &gt; 18 years, severe obesity is defined as a body mass index (BMI) &gt; 40
             kg/m2.

          -  Evidence of hunger/hyperphagia at screening.

               -  Participants ≥8 years of age will complete the Patient-Reported Hunger
                  Questionnaire (Appendix 1).

               -  For participants who are ≤12 years of age will have a Parent or Caregiver
                  complete the Parent/Guardian Observation Questionnaire (Appendix 2).

               -  Therefore, participants between ages 8-12 years of age will have both Direct
                  Patient reported and Parent/Guardian Observer questionnaires completed.

          -  Sufficient venous access and ability to tolerate venipuncture. If unable to tolerate
             venipuncture, sample is to be collected via buccal swab.

          -  Optional phenotypic screening features present (when diagnosed/available) which will
             be given priority for DNA collection when screening and recruiting subjects, include:

          -  For all 3 potential genetic causes: Presence of normal weight sibling(s), defined as
             weight ≤ 50%tile (or +1 SD) weight for age range if age 2 to 18 years, or BMI &lt;30
             kg/m2 if adult, and history of hypoglycemia after birth and in infancy.

               -  POMC: Red hair, Fitzpatrick type 1 skin, central adrenal insufficiency, on
                  current adrenal hormone replacement.

               -  PCSK1: Diarrhea, malabsorption as infants; insulin resistance. (These patients
                  may not report/recall hyperphagia or early onset of weight gain in infancy or
                  early childhood due to their initial diarrhea presentation and other GI
                  symptoms).

               -  LepR: Hypogonadism, central hypothyroidism, short stature, on testosterone or
                  estrogen replacement if adult.

        Exclusion Criteria:

        - Prior craniopharyngioma or other hypothalamic brain region surgery.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fred T Fiedorek, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Rhythm Pharmceuticals, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>H Connors</last_name>
    <email>hconnors@rhythmtx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington, D.C.</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nazrat Mirza, MD, ScD</last_name>
      <phone>202-476-3948</phone>
      <email>NMIRZA@childrensnational.org</email>
    </contact>
    <investigator>
      <last_name>Nazrat Mirza, MD, ScD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beverly P Giordano</last_name>
      <phone>352-294-5280</phone>
      <email>bgiordano@peds.ufl.edu</email>
    </contact>
    <investigator>
      <last_name>Jennifer Miller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Translational Research Inst. for Metabolism and Diabetes</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patty Ford</last_name>
      <phone>407-303-7107</phone>
      <email>trimd@flhosp.org</email>
    </contact>
    <investigator>
      <last_name>Steven R Smith, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cohen Children's Medical Center of NY</name>
      <address>
        <city>Lake Success</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Lowell</last_name>
      <phone>516-472-3750</phone>
    </contact>
    <investigator>
      <last_name>Parissa Salemi, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wendy Chung</last_name>
      <phone>212-851-5313</phone>
    </contact>
    <investigator>
      <last_name>Wendy K Chung, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Hospital</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristi Romero</last_name>
      <phone>919-684-1352</phone>
      <email>kristi.romero@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Michael Freemark, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hospital, Center for Healthy Weight and Nutrition</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jinyu Xu, PhD, MPH</last_name>
      <phone>614-722-3598</phone>
      <email>Jinyu.Xu@NationwideChildrens.org</email>
    </contact>
    <investigator>
      <last_name>Ihuoma Eneli, MD, MS, FAAP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Tennesseee Health Science Center</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raquel Mack, RN</last_name>
      <phone>901-287-6869</phone>
      <email>rmack7@uthsc.edu</email>
    </contact>
    <investigator>
      <last_name>Joan Han, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashley Shoemaker, MD</last_name>
      <phone>615-343-8116</phone>
      <email>Ashley.H.Shoemaker@Vanderbilt.edu</email>
    </contact>
    <investigator>
      <last_name>Ashley Shoemaker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cordelia Franklin, BS</last_name>
      <phone>206-884-8150</phone>
      <email>cordelia.franklin@seattlechildrens.org</email>
    </contact>
    <investigator>
      <last_name>Christian Roth, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Alberta</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2E1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lucila Triador, MSc</last_name>
      <phone>780-293-3449</phone>
      <email>triador@ualberta.ca</email>
    </contact>
    <investigator>
      <last_name>Andrea Haqq, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Hospital of Patras</name>
      <address>
        <city>Patras</city>
        <zip>26504</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bessie E. Spiliotis, MD</last_name>
      <phone>306977000947</phone>
      <email>besspil@endo.gr</email>
    </contact>
    <investigator>
      <last_name>Bessie E. Spiliotis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Greece</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 26, 2016</study_first_submitted>
  <study_first_submitted_qc>July 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2016</study_first_posted>
  <last_update_submitted>August 24, 2017</last_update_submitted>
  <last_update_submitted_qc>August 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>POMC</keyword>
  <keyword>PCSK1</keyword>
  <keyword>Pro-opiomelanocortin</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

